Free Trial

Avalon GloboCare (ALBT) Competitors

Avalon GloboCare logo
$2.35 -0.07 (-2.89%)
Closing price 04:00 PM Eastern
Extended Trading
$2.22 -0.13 (-5.32%)
As of 05:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ALBT vs. MIRA, NAII, BCTX, LGVN, JATT, BLRX, CING, MRKR, BIVI, and QTTB

Should you be buying Avalon GloboCare stock or one of its competitors? The main competitors of Avalon GloboCare include MIRA Pharmaceuticals (MIRA), Natural Alternatives International (NAII), Briacell Therap (BCTX), Longeveron (LGVN), JATT Acquisition (JATT), BioLineRx (BLRX), Cingulate (CING), Marker Therapeutics (MRKR), BioVie (BIVI), and Q32 Bio (QTTB). These companies are all part of the "pharmaceutical products" industry.

Avalon GloboCare vs. Its Competitors

MIRA Pharmaceuticals (NASDAQ:MIRA) and Avalon GloboCare (NASDAQ:ALBT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

In the previous week, Avalon GloboCare had 4 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 5 mentions for Avalon GloboCare and 1 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 0.96 beat Avalon GloboCare's score of 0.82 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
MIRA Pharmaceuticals Positive
Avalon GloboCare Positive

MIRA Pharmaceuticals has higher earnings, but lower revenue than Avalon GloboCare. MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MIRA PharmaceuticalsN/AN/A-$7.85M-$0.51-3.96
Avalon GloboCare$1.37M3.25-$7.90M-$19.96-0.12

MIRA Pharmaceuticals has a net margin of 0.00% compared to Avalon GloboCare's net margin of -647.29%. Avalon GloboCare's return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
MIRA PharmaceuticalsN/A -341.08% -272.93%
Avalon GloboCare -647.29%N/A -50.13%

MIRA Pharmaceuticals has a beta of 1.72, suggesting that its stock price is 72% more volatile than the S&P 500. Comparatively, Avalon GloboCare has a beta of -0.03, suggesting that its stock price is 103% less volatile than the S&P 500.

35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are owned by institutional investors. 6.7% of MIRA Pharmaceuticals shares are owned by company insiders. Comparatively, 37.3% of Avalon GloboCare shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

MIRA Pharmaceuticals presently has a consensus price target of $14.00, indicating a potential upside of 593.07%. Given MIRA Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe MIRA Pharmaceuticals is more favorable than Avalon GloboCare.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MIRA Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.33
Avalon GloboCare
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

MIRA Pharmaceuticals beats Avalon GloboCare on 10 of the 16 factors compared between the two stocks.

Get Avalon GloboCare News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALBT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALBT vs. The Competition

MetricAvalon GloboCareMED IndustryMedical SectorNASDAQ Exchange
Market Cap$4.45M$2.93B$5.50B$9.39B
Dividend YieldN/A2.46%4.25%4.09%
P/E Ratio-0.1220.3128.1019.86
Price / Sales3.25261.57402.2879.25
Price / CashN/A42.3835.5357.53
Price / Book-0.217.838.265.72
Net Income-$7.90M-$55.11M$3.24B$257.80M
7 Day Performance-9.27%2.18%0.50%1.06%
1 Month Performance-22.44%12.98%7.99%11.30%
1 Year Performance-67.96%1.98%28.68%17.00%

Avalon GloboCare Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALBT
Avalon GloboCare
1.3598 of 5 stars
$2.35
-2.9%
N/A-65.0%$4.45M$1.37M-0.125Gap Down
MIRA
MIRA Pharmaceuticals
2.457 of 5 stars
$1.15
-4.2%
$14.00
+1,117.4%
+130.9%$20.30MN/A-2.252
NAII
Natural Alternatives International
1.4826 of 5 stars
$3.32
+2.2%
N/A-39.1%$20.08M$125.48M-2.39290
BCTX
Briacell Therap
1.8852 of 5 stars
$2.89
-0.7%
$32.00
+1,007.3%
-94.4%$19.72MN/A-0.358
LGVN
Longeveron
3.031 of 5 stars
$1.29
-1.5%
$8.67
+571.8%
-58.5%$19.56M$2.39M-0.2120
JATT
JATT Acquisition
N/A$1.13
+0.9%
N/A-64.8%$19.49MN/A0.003High Trading Volume
BLRX
BioLineRx
2.6497 of 5 stars
$4.32
-3.8%
$26.00
+501.9%
-85.9%$19.14M$22.34M-0.4940
CING
Cingulate
2.954 of 5 stars
$4.42
+3.3%
$26.00
+488.2%
+1,276.5%$18.17MN/A-0.5220
MRKR
Marker Therapeutics
4.3216 of 5 stars
$1.57
-1.9%
$13.17
+738.6%
-72.6%$18.10M$6.59M-1.1860Gap Up
Trading Halted
BIVI
BioVie
1.0695 of 5 stars
$8.10
-15.6%
N/A+62.6%$17.83MN/A-1.0210Positive News
QTTB
Q32 Bio
2.7077 of 5 stars
$1.36
-5.6%
$12.17
+794.6%
-89.6%$17.57M$1.16M-0.2839

Related Companies and Tools


This page (NASDAQ:ALBT) was last updated on 7/17/2025 by MarketBeat.com Staff
From Our Partners